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Introduction
Staging systems for cancer are essential for determining 
treatment plans, communicating among medical personnel, 
and accurately predicting survival. A widely accepted 
and used cancer staging system is the tumor, node, and 
metastasis (TNM) system. The TNM system describes 
the anatomical extent of disease based on assessment of 
three components: T is the extent of the primary tumor, 
N is the absence or presence and extent of regional lymph 
node metastasis, and M is the absence or presence of 
distant metastasis. The American Joint Committee on 
Cancer (AJCC)/Union for International Cancer Control 
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(UICC) system is based on the TNM descriptor and has 
been adopted worldwide. For esophageal cancer, the 7th 
edition of the AJCC staging system for esophageal cancer 
was published in 2009 based on a Worldwide Esophageal 
Cancer Collaboration (WECC) database (1) and 8th edition 
of the AJCC/UICC system was published in 2017. In 
addition to the AJCC system, Japan has its own esophageal 
cancer staging system. The current Japanese staging 
system is the 11th edition of the Japanese classification for 
esophageal cancer, based on a comprehensive esophageal 
cancer registry in Japan (2). Compared to the AJCC 
system, the Japanese classification has a different lymph 
node mapping system for esophageal cancer and different 
definitions of N staging and stage grouping compared 
to the AJCC system. The Japanese classification reflects 
the extensive experiences of Japanese surgeons who have 
performed uniform operations for esophageal cancer. The 
AJCC system is based on a worldwide international database 
and novel statistical methods.
Because of the two different staging systems for 
esophageal cancer, surgeons and clinicians are confused 
about which staging system is appropriate for clinical 
situations and should be applied. A cancer staging system 
has to predict survival well and be easy to use. Therefore, 
this retrospective study investigated which staging system 
was more appropriate for esophageal cancer. Predictive 
powers for prognosis of the 7th and 8th AJCC staging 
systems and the 11th Japanese classification for esophageal 
cancer were calculated and compared. 
Methods
This retrospective study was approved by the Institutional 
Review Board of our hospital (4-2017-0769). Records 
were retrospectively reviewed for 143 patients who 
underwent  esophagectomy with  mediast ina l  and 
abdominal lymphadenectomy for esophageal squamous 
cell carcinoma (ESCC) between January 2006 and 
July 2015. During the study periods, total 184 patients 
received the esophagectomy, and 20 patients received 
the neoadjuvant therapy.  Exclusion criteria  were 
neoadjuvant therapy, incomplete resection (R1 or R2 
resection), salvage operation, operative mortality, and 
other pathology including esophageal adenocarcinoma. 
Because more than 90% of esophageal cancer in East 
Asia is squamous cell carcinoma, we analyzed patients 
with ESCC patients only for data consistency. Chest and 
abdominal computed tomography (CT), positron emission 
tomography-computed tomography (PET-CT), and 
esophagogastroduodenoscopy with endoscopic ultrasound 
were performed preoperatively. After operation, adjuvant 
chemotherapy based on cisplatin was done if patients have 
metastatic lymph nodes. In case of T3 or T4a, adjuvant 
radiotherapy was also performed. During follow-up, chest 
and abdomen CT scans were obtained at 6-month intervals, 
and esophagogastroduodenoscopy was conducted annually 
after operation. Locoregional recurrence was defined as 
occurring at the anastomosis site or mediastinum and 
abdomen where lymph node dissection was performed. 
Distant recurrence was defined as that found in tissues 
outside of the operative field such as lung, brain, liver, 
adrenal glands, bone, or other locations. Recurrence was 
diagnosed based on PET-CT scans and chest-abdomen 
CT scans, with tissue biopsy of suspected recurrent lesions 
performed if clinically possible. All patients were followed 
without loss. 
Staging and lymph node map
As an institutional policy, surgical specimens were routinely 
dissected after the operation to accurately define lymph node 
stations. We applied a Japanese lymph node map for defining 
lymph node station and pathology staging (2). Because the 
AJCC system and Japanese classification had different lymph 
node maps, all dissected lymph nodes were reclassified 
according to the AJCC 7th and 8th lymph node map of 
esophageal cancer (3,4). Based on these results, patients were 
assigned three stages based on 7th AJCC staging system, 8th 
AJCC staging system, and 11th Japanese classification. 
Statistical analysis
Statistical analysis used the open source statistical software 
R (http://www.R-project.org). Clinical and pathological 
parameters were described as mean ± standard deviation 
for continuous variables and frequency (%) for categorical 
variables. Overall survival (OS) was measured from date of 
operation to date of death from any cause or last clinical 
follow-up. Disease-free survival (DFS) was measured from 
date of operation to date of recurrence or death from any 
cause or last clinical follow-up. The Kaplan-Meier method 
and log-rank test were used for univariate analysis for 
survival, and a Cox proportional hazard model was used 
to calculate hazard ratios (HRs). Survcomp packages for 
performance assessment and calculation of concordance 
index (C-index) were used to calculate predictive power for 
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survival and to compare Cox proportional hazard models (5). 
All tests were two-sided, and the criterion for significance 
was P<0.05.
Results
Patient demographics, recurrences, and survival
Basic patient characteristics are described in Table 1. Mean 
patient age was 63.14±8.10 years, and 131 (91.6%) patients 
were men. Median follow-up was 47.73 (6.27–134.40) months. 
Patients were classified in three stages (Table 2). Although T 
stagings were similar for the three staging systems, and in 
situ lesions were defined as T1a in the Japanese classification 
and Tis in the AJCC system. Patients showed different N 
and M staging. Four patients had metastatic lymph nodes 
Table 1 Basic characteristics of 143 patients and their tumors
Variables Value
Age (years) 63.14±8.10
Male 131 (91.6%)
Location
Upper 10 (7.0%)
Mid 81 (56.6%) 
Lower 52 (36.4%)
Differentiation
Well-differentiated 32 (22.4%)
Moderately differentiated 99 (69.2%)
Poorly differentiated 12 (8.4%)
Table 2 Staging based on the staging systems
Staging AJCC 7th staging AJCC 8th staging Japanese 11th staging
T staging, n (%)
0 3 (2.1) 3 (2.1) 0
1a 32 (22.4) 32 (22.4) 35 (24.5)
1b 69 (48.3) 69 (48.3) 69 (48.3)
2 13 (9.1) 13 (9.1) 13 (9.1)
3 26 (18.2) 26 (18.2) 26 (18.2) 
N staging, n (%)
0 81 (56.6) 81 (56.6) 81 (56.6)
1 35 (24.5) 36 (25.2) 37 (25.9)
2 23 (16.1) 22 (15.4) 16 (11.2)
3 4 (2.8) 4 (2.8) 9 (6.3)
M staging, n (%)
0 143 (100.0) 139 (97.2) 143 (100.0))
1 0 4 (2.8) 0
Stage grouping, n (%)
0 3 (2.1) 3 (2.1) 32 (22.4)
I 69 (48.3) 67 (46.8) 37 (25.9)
II 42 (29.4) 37 (25.9) 50 (35.0)
III 29 (20.3) 30 (21.0) 24 (16.8)
IV 0 6 (4.2) 0
AJCC, the American Joint Committee on Cancer.
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at the supraclavicular fossa with M0 disease based on the 
AJCC 7th edition lymph node map, upstaged to M1 in the 
AJCC 8th edition because that map defines supraclavicular 
lymph node metastasis as distant metastasis. Patients also 
showed different stage groupings (Table 2).
For all 143 patients, 5-year OS was 74.1% and DFS 
was 72.5% (Figure 1A,B). During follow-up, recurrences 
developed in 30 (20.9%) patients. Locoregional recurrences 
occurred in 4 (2.8%) patients; 2 in upper mediastinum, 
1 subcarinal lymph node, 1 in right supraclavicular fossa. 
Distant recurrences occurred in 26 (18.2%) patients.
Comparison of staging systems according to N staging
Survival differences were measured according to N staging. 
Based on N staging of the AJCC 7th staging system, DFS 
was well stratified (Figure 2A). The 5-year DFS by stage was 
81.5% for N0, 71.3% for N1, 55.3% for N2, and 0% for 
N3 (P<0.001). Based on N staging of the AJCC 8th staging 
system, DFS was well stratified (Figure 2B). The 5-year 
DFS was 81.5% for N0, 72.0% for N1, 53.2% for N2, and 
0% for N3 (P<0.001). For the Japanese N staging system, 
DFS was well stratified (Figure 2C). The 5-year DFS was 
81.5% for N0, 71.2% for N1, 51.6% for N2, and 33.3% for 
and N3 (P<0.001). For patients with N3 cancer, N3 in the 
Japanese staging system had a higher survival than N3 in 
the AJCC staging system.
HRs for N staging for each stage system are documented 
in Table 3. HRs increased as N stage increased for each 
staging system. C-indexes for N staging were 0.755 [95% 
confidence interval (CI), 0.650–0.860] for AJCC 7th staging, 
0.755 (95% CI, 0.650–0.860) for AJCC 8th staging, and 
Figure 1 Survival curves. (A) OS of all patients; (B) DFS of all patients. OS, overall survival; DFS, disease-free survival.
Figure 2 Survival curves. (A) DFS according to N stage of the AJCC 7th edition; (B) DFS according to N stage of the AJCC 8th edition; (C) 
DFS according to N stage of the Japanese 11th classification. AJCC, the American Joint Committee on Cancer; DFS, disease-free survival.
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5-year DFS N0 vs. N2, P=0.002
in N0; 81.5% N0 vs. N3, P<0.001
in N1; 72% N1 vs. N3, P<0.001
in N2; 53.2% N2 vs. N3, P=0.001
in N3; 0%
5-year DFS N0 vs. N2, P=0.006
in N0; 81.5% N0 vs. N3, P<0.001
in N1; 71.2% N1 vs. N3, P=0.001
in N2; 51.6%  
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Figure 3 Survival curves. (A) DFS according to stage grouping of the AJCC 7th edition; (B) DFS according to stage grouping of the AJCC 
8th edition; (C) DFS according to stage grouping of the Japanese 11th classification. AJCC, the American Joint Committee on Cancer; DFS, 
disease-free survival.
Table 3 Cox proportional model for N staging 
Factors
AJCC 7th staging AJCC 8th staging Japanese 11th classification 
HR (95% CI) P HR (95% CI) P HR (95% CI) P
N staging
0 Reference Reference Reference
1 1.555 (0.679–3.559) 0.296 1.510 (0.660–3.455) 0.330 1.679 (0.754–3.741) 0.05
2 3.195 (1.431–7.7137) 0.005 3.383 (1.514–7.556) 0.003 3.121 (1.265–7.699) 0.013
3 35.697 (10.593–120.297) <0.001 35.761 (10.611–120.519) <0.001 6.350 (2.448–16.474) <0.001
Concordance index 0.755 (0.650–0.860) 0.755 (0.650–0.860) 0.734 (0.634–0.835)
AJCC, the American Joint Committee on Cancer; HR, hazard ratio; CI, confidence interval.
0.734 (95% CI, 0.634–0.835) for the Japanese 11th system. 
C-indexes for AJCC N staging was slightly higher than 
for the Japanese classification, with no significant different 
(AJCC 7th vs. Japanese 11th P=0.11, AJCC 8th vs. Japanese 
11th P=0.11).
Comparison of the three staging systems according to 
grouping
Survival differences were measured according to stage 
grouping. Based on stage grouping for the AJCC 7th staging 
system, DFS was well stratified (Figure 3A). The 5-year 
DFS was 100% for patients with stage 0 cancer, 85.2% for 
stage I, 69.6% for stage II, and 43.4% for stage III (P<0.001). 
Based on stage grouping of the AJCC 8th staging system, 
DFS was well stratified (Figure 3B). The 5-year DFS was 
100% for patients with stage 0 cancer, 84.9% for stage I, 
73.1% for stage II, 49.3% for stage III, and 33.3% for stage 
IV (P<0.001). For the Japanese stage-grouping system, DFS 
was well stratified (Figure 3C). The 5-year DFS was 93.5% 
for patients with stage 0 cancer, 80.1% for stage I, 72.3% 
for stage II, and 32.4% for stage III (P<0.001).
HRs for stage groping for each staging system are 
documented in Table 4. HRs increased as N stage increased 
for each staging system. C-indexes for staging grouping was 
0.813 (95% CI, 0.732–0.896) for AJCC 7th staging, 0.805 
(95% CI, 0.726–0.885) for AJCC 8th staging, and 0.837 
(95% CI, 0.766–0.908) for 11th Japanese classification. The 
c-index for staging grouping for the Japanese system was 
slightly higher than the c-indexes for the AJCC system, 
although without significant differences (AJCC 7th vs. AJCC 
8th P=0.250, AJCC 8th vs. Japanese 11th P=0.964, and AJCC 
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Table 4 Cox proportional model for staging groupings 
Factors
AJCC 7th staging AJCC 8th staging Japanese 11th classification 
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Stage grouping
0 Reference Reference Reference
I 2.886 (0.581–14.327) 0.195
II 2.855 (1.220–6.683) 0.016 2.452 (0.996–6.037) 0.051 5.646 (1.281–24.879) 0.022
III 7.195 (3.161–16.378) <0.001 5.618 (2.450–12.881) <0.001 21.178 (4.829–92.883) <0.001
IV – – 12.019 (3.645–39.633) <0.001 – –
Concordance index 0.813 (0.732–0.896) 0.805 (0.726–0.885) 0.837 (0.766–0.908)
AJCC, the American Joint Committee on Cancer; HR, hazard ratio; CI, confidence interval.
7th vs. Japanese 11th P=0.837). 
Discussion
Cancer stage at the time of diagnosis is a key factor for 
defining prognosis and is a critical element in determining 
appropriate treatment based on the experience and 
outcomes of groups of patients with similar stage. A widely 
used cancer staging system is based on the TNM system 
developed by Pierre Denoix in the 1940s. For staging 
esophageal cancer, the AJCC/UICC TNM staging system 
is applied worldwide, although the Japanese classification 
is also used in Japan. Each staging system has its own 
characteristics. The first UICC esophageal cancer staging 
system was proposed in 1968, and the first AJCC staging 
system in 1977 (6). Since 1987, close collaboration between 
the AJCC and the UICC has resulted in uniform and 
identical definitions and stage groupings of cancers for all 
anatomical sites. At the request of the AJCC, the WECC 
was inaugurated in 2006 (6). The 7th and 8th AJCC/UICC 
staging systems were proposed by WECC. The 8th staging 
system analyzed the data of 22,653 patients from 33 WECC 
institutions in 6 continents and 13 countries (7). Since the 
7th AJCC staging system, this system has applied modern 
machine-learning analysis and random forest analysis (8). 
Therefore, the AJCC esophageal cancer stage system 
is a scientific staging system based on large, worldwide 
databases and novel statistical techniques. However, 
Japanese institutions did not participate in WECC, and 
Japanese data were not included in the WECC database (7). 
Japanese institutions proposed the first edition of Japanese 
classification in 1969, and the latest is the 11th edition 
published in 2015 (2). The recent Japanese classifications 
are based on a comprehensive registry of esophageal 
cancer with very high consistency in surgical policies 
and techniques whereas WECC data included different 
countries and surgical policies.
The major differences in the two staging systems are in 
N category and stage grouping. In the AJCC staging system, 
N category is classified by the number of metastatic lymph 
nodes. In the Japanese classification, the N category is 
classified by the spread of metastasis-positive lymph nodes. 
The AJCC N category reflects the burden of the primary 
tumor, such as malignancies in the gastrointestinal tract, 
breast, and kidney. This system is easy to use with surgical 
specimens, but difficult to apply for preoperative clinical 
staging. The current preoperative imaging system for the 
work-up of esophageal cancer has limitations in resolution (9). 
The accurate prediction of the number of metastatic 
lymph nodes in clinical staging is nearly impossible for 
esophageal cancer and other malignancies. Inaccuracy 
and the high possibility of N stage migration are major 
limitations of the N staging system based on the number 
of metastatic lymph nodes. In contrast, the N category of 
the Japanese classification is based on the spread of lymph 
nodes, which is complex because the definition of N differs 
according to the location of the primary lesion. Pathologists 
have difficulty defining lymph node stations in resected 
pathologic specimens. Therefore, the operator must dissect 
lymph nodes from surgical specimens to define lymph 
nodes stations accurately. In spite of these complexities, 
the Japanese classification can give additional information 
to surgeons about the extent of lymphadenectomy by 
N category. In addition to N category, the Japanese 
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classification defines the concepts of D1–D3 dissection, 
which indicates extent of lymphadenectomy. Using these 
definitions, a surgeon can plan for extent of dissection 
based on the location of primary lesions. Similar to these 
systems, the N categories of the AJCC system and Japanese 
classification have their own advantages and limitations. 
For survival prediction, these two N category systems were 
similar in our results. This finding implied that both N 
categories could be applied in clinical situations for survival 
prediction.
Another difference between the two systems is stage 
grouping. In the AJCC system, prognostic stage grouping 
and anatomic stage grouping are used. The AJCC system 
included non-anatomical factors into stage classification to 
improve the prediction power of survival. Differentiation 
and location have been included in prognostic staging in 
the AJCC system since the 7th edition. In the 8th edition, 
the AJCC system had different staging groupings according 
to treatment status: clinical, pathological, and neoadjuvant 
pathologic (7,10,11). In addition, the AJCC staging system 
has different stage groupings according to pathology. 
Esophageal adenocarcinoma and squamous cell carcinoma 
have had different stage groupings since the 7th edition. 
Finally, in the 8th edition, the AJCC system has five stage-
grouping systems staging groupings according to treatment 
status (clinical, pathological, and neoadjuvant pathologic 
stage) and pathology. As a result, the AJCC system has five 
stage grouping systems in the 8th edition (3). This strategy 
results in complex stage grouping that is difficult to apply in 
clinical situations. The original intent of the TNM system 
was to be a staging system based on anatomical factors 
only. The inclusion of non-anatomical factors in the TNM 
staging system does not follow the original intent of the 
TNM system. In contrast, the Japanese classification does 
not include non-anatomical factors such as differentiation 
and location in stage grouping and it has uniform stage 
grouping regardless of pathology and treatment status. 
Therefore the stage grouping of Japanese system is easy to 
use. A comparison of the three stage groupings showed that 
the stage grouping of the Japanese classification showed 
slightly better survival prediction although not significantly 
different. This finding implies that even a simple stage 
grouping without non-anatomical factors could have similar 
or slightly better survival prediction compared to a complex 
stage grouping system. If a simple and easy-to-use staging 
system is desired, further editions of stage groupings need 
to be simplified.
Each staging system had its own lymph node map and 
definition of regional lymph nodes. For example, the 
supraclavicular lymph nodes (No. 1 in the AJCC 7th edition 
and No. 104 in the 11th Japanese classification) are defined 
as regional lymph nodes in the AJCC 7th edition and the 
11th Japanese classification but as distant lymph nodes in 
the AJCC 8th edition. In the 11th Japanese classification, 
lymph node metastasis to the supraclavicular lymph nodes 
is defined as N2 in cervical, upper, and middle thoracic 
esophageal cancer; N3 in lower thoracic esophageal cancer; 
and distant lymph nodes in abdominal esophageal cancer. 
If patients have suspicious metastatic lymph nodes in the 
supraclavicular area, surgical indications could differ based 
on staging system. In the 11th Japanese classification, a 
patient would have loco-regional disease and could be 
indicated for surgical resection; in the AJCC 8th edition, the 
patient would have distant metastasis, and surgical resection 
would not be indicated. The issue of which staging system 
to use is related to prediction of survival, convenience of 
use, and selection of the indication for surgery. However, 
the issues of which lymph node map is appropriate for 
esophageal cancer can be studied only in a comparison 
of survival predictions. In our data, only 4 patients had 
metastasis in the supraclavicular lymph nodes, and the 
survival differences according to supraclavicular lymph node 
metastasis could not be analyzed. To study this issue, a large 
cohort is needed.
Our study has several limitations. First, we analyzed 
patients with ESCC and excluded patients who received 
neoadjuvant treatment. Because more than 90% of 
esophageal cancers are ESCCs in East Asia and a small 
number of patients received neoadjuvant therapy in our 
institution, we analyzed pathologic stage only in patients 
with ESCC. For esophageal adenocarcinoma, our results 
should be applied cautiously. Second, differences such as 
in the definition of esophagogastric junction tumors were 
not analyzed. Last, the number of patients was relatively 
small. Although stage grouping changed from the AJCC/
UICC 7th to 8th editions, the predictive powers for survival 
did not increase in our data. This result might be related to 
the small number of patients. In the AJCC staging system, 
stages I, II, and III are subdivided into IA, IB, IIA, IIB, 
IIIA, and IIIB, but we did not calculate survival differences 
between subdivided stages due to the small number of 
patients.
In conclusion, N staging and stage grouping of the 11th 
Japanese classification and 7th and 8th AJCC staging systems 
for ESCC showed similar predictive power for DFS. Both 
systems can be applied in clinical situations. 
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